

By: Senator(s) Jordan, Jackson (11th)

To: Drug Policy; Judiciary,  
Division A

SENATE BILL NO. 2892  
(As Sent to Governor)

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,  
2 TO INCLUDE FURANYL FENTANYL AND U-47700 AS SCHEDULE I CONTROLLED  
3 SUBSTANCES AND TO EXCLUDE CANNABIDIOL FROM CONTROL UNDER SCHEDULE  
4 I UNDER CERTAIN CIRCUMSTANCES; TO AMEND SECTION 41-29-115,  
5 MISSISSIPPI CODE OF 1972, TO INCLUDE DRONABINOL ORAL SOLUTION AND  
6 THIAFENTANIL AS SCHEDULE II CONTROLLED SUBSTANCES; AND FOR RELATED  
7 PURPOSES.

8 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

9 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is  
10 amended as follows:

11 41-29-113. The controlled substances listed in this section  
12 are included in Schedule I.

13 **SCHEDULE I**

14 (a) **Opiates.** Any of the following opiates, including their  
15 isomers, esters, ethers, salts and salts of isomers, esters and  
16 ethers, unless specifically excepted, whenever the existence of  
17 these isomers, esters, ethers and salts is possible within the  
18 specific chemical designation:

19 (1) Acetyl-alpha-methylfentanyl;



- 20 (2) Acetyl Fentanyl  
21 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;  
22 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
23 cyclohexylmethyl]benzamide);  
24 (4) Acetylmethadol;  
25 (5) Allylprodine;  
26 (6) Alphacetylmethadol, except levo-alphacetylmethadol  
27 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);  
28 (7) Alphameprodine;  
29 (8) Alphamethadol;  
30 (9) Alpha-methylfentanyl;  
31 (10) Alpha-methylthiofentanyl;  
32 (11) Benzethidine;  
33 (12) Betacetylmethadol;  
34 (13) Beta-hydroxyfentanyl;  
35 (14) Beta-hydroxy-3-methylfentanyl;  
36 (15) Betameprodine;  
37 (16) Betamethadol;  
38 (17) Betaprodine;  
39 (18) Clonitazene;  
40 (19) Dextromoramide;  
41 (20) Diampromide;  
42 (21) Diethylthiambutene;  
43 (22) Difenoazin;  
44 (23) Dimenoxadol;



45 (24) Dimepheptanol;

46 (25) Dimethylthiambutene;

47 (26) Dioxaphetyl butyrate;

48 (27) Dipipanone;

49 (28) Ethylmethylthiambutene;

50 (29) Etonitazene;

51 (30) Etoxeridine;

52 (31) Furanyl Fentanyl,

53 N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide;

54 ( \* \* \*32) Furethidine;

55 ( \* \* \*33) Hydroxypethidine;

56 ( \* \* \*34) Ketobemidone;

57 ( \* \* \*35) Levomoramide;

58 ( \* \* \*36) Levophenacylmorphane;

59 ( \* \* \*37) 3-methylfentanyl;

60 ( \* \* \*38) 3-methylthiofentanyl;

61 ( \* \* \*39) Morpheridine;

62 ( \* \* \*40) MPPP

63 (1-methyl-4-phenyl-4-propionoxypiperidine);

64 ( \* \* \*41)

65 N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its isomers,

66 esters, ethers, salts and salts of isomers, esters and ethers

67 (other names: Butyryl fentanyl);

68 ( \* \* \*42)

69 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylprop



70 ionamide, its isomers, esters, ethers, salts and salts of isomers,  
71 esters and ethers (other names: beta-hydroxythiofentanyl);

72 ( \* \* \*43) Noracymethadol;

73 ( \* \* \*44) Norlevorphanol;

74 ( \* \* \*45) Normethadone;

75 ( \* \* \*46) Norpipanone;

76 ( \* \* \*47) Para-fluorofentanyl;

77 ( \* \* \*48) PEPAP

78 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);

79 ( \* \* \*49) Phenadoxone;

80 ( \* \* \*50) Phenampromide;

81 ( \* \* \*51) Phenomorphan;

82 ( \* \* \*52) Phenoperidine;

83 ( \* \* \*53) Piritramide;

84 ( \* \* \*54) Proheptazine;

85 ( \* \* \*55) Properidine;

86 ( \* \* \*56) Propiram;

87 ( \* \* \*57) Racemoramide;

88 ( \* \* \*58) Thiofentanyl;

89 ( \* \* \*59) Tilidine;

90 ( \* \* \*60) Trimeperidine \* \* \*;

91 (61) U-47700,

92 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide.

93 (b) \* \* \* **Opium derivatives.** Any of the following opium  
94 derivatives, their salts, isomers and salts of isomers, unless



95 specifically excepted, whenever the existence of these salts,  
96 isomers and salts of isomers is possible within the specific  
97 chemical designation:

- 98 (1) Acetorphine;
- 99 (2) Acetyldihydrocodeine;
- 100 (3) Benzylmorphine;
- 101 (4) Codeine methylbromide;
- 102 (5) Codeine-N-Oxide;
- 103 (6) Cyprenorphine;
- 104 (7) Desomorphine;
- 105 (8) Dihydromorphine;
- 106 (9) Drotebanol;
- 107 (10) Etorphine \* \* \* (except hydrochloride salt);
- 108 (11) Heroin;
- 109 (12) Hydromorphinol;
- 110 (13) Methyldesorphine;
- 111 (14) Methyldihydromorphine;
- 112 (15) Monoacetylmorphine;
- 113 (16) Morphine methylbromide;
- 114 (17) Morphine methylsulfonate;
- 115 (18) Morphine-N-Oxide;
- 116 (19) Myrophine;
- 117 (20) Nicocodeine;
- 118 (21) Nicomorphine;
- 119 (22) Normorphine;



120 (23) Pholcodine;

121 (24) Thebacon.

122 (c) **Hallucinogenic substances.** Any material, compound,  
123 mixture or preparation which contains any quantity of the  
124 following substances, their salts, isomers (whether optical,  
125 positional, or geometric) and salts of isomers, unless  
126 specifically excepted, whenever the existence of these salts,  
127 isomers and salts of isomers is possible within the specific  
128 chemical designation:

129 (1) Alpha-ethyltryptamine;

130 (2) 4-bromo-2,5-dimethoxy-amphetamine;

131 (3) 4-bromo-2,5-dimethoxyphenethylamine;

132 (4) 2,5-dimethoxyamphetamine;

133 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);

134 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine  
135 2C-T-7);

136 (7) 4-methoxyamphetamine;

137 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;

138 (9) 4-methyl-2,5-dimethoxy-amphetamine;

139 (10) 3,4-methylenedioxy amphetamine;

140 (11) 3,4-methylenedioxymethamphetamine (MDMA);

141 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known  
142 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl  
143 MDA, MDE, MDEA);



- 144 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also  
145 known as N-hydroxy MDA, N-OHMDA, and  
146 N-hydroxy-alpha-methyl-3,4 (methylenedioxy)phenethylamine);  
147 (14) 3,4,5-trimethoxy amphetamine;  
148 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);  
149 (16) Alpha-methyltryptamine (also known as AMT);  
150 (17) Bufotenine;  
151 (18) Diethyltryptamine;  
152 (19) Dimethyltryptamine;  
153 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);  
154 (21) Ibogaine;  
155 (22) Lysergic acid diethylamide (LSD);  
156 (23) (A) Marijuana (Cannabidiol contained in a legend  
157 drug product approved by the Federal Food and Drug Administration  
158 or obtained under Section 41-29-136 is exempt under Schedule I);  
159 (B) Hashish;  
160 (24) Mescaline;  
161 (25) Parahexyl;  
162 (26) Peyote;  
163 (27) N-ethyl-3-piperidyl benzilate;  
164 (28) N-methyl-3-piperidyl benzilate;  
165 (29) Psilocybin;  
166 (30) Psilocyn;  
167 (31) Tetrahydrocannabinols, meaning  
168 tetrahydrocannabinols contained in a plant of the genus Cannabis



169 (cannabis plant), as well as the synthetic equivalents of the  
170 substances contained in the cannabis plant, or in the resinous  
171 extractives of such plant, and/or synthetic substances,  
172 derivatives, and their isomers with similar chemical structure and  
173 pharmacological activity to those substances contained in the  
174 plant such as the following:

175 (A) 1 cis or trans tetrahydrocannabinol;

176 (B) 6 cis or trans tetrahydrocannabinol;

177 (C) 3,4 cis or trans tetrahydrocannabinol.

178 (Since nomenclature of these substances is not  
179 internationally standardized, compounds of these structures,  
180 regardless of atomic positions are covered.)

181 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)

182 However, the following products are exempted from control:

183 (i) THC-containing industrial products made  
184 from cannabis stalks (e.g., paper, rope and clothing);

185 (ii) Processed cannabis plant materials used  
186 for industrial purposes, such as fiber retted from cannabis stalks  
187 for use in manufacturing textiles or rope;

188 (iii) Animal feed mixtures that contain  
189 sterilized cannabis seeds and other ingredients (not derived from  
190 the cannabis plant) in a formula designed, marketed and  
191 distributed for nonhuman consumption;

192 (iv) Personal care products that contain oil  
193 from sterilized cannabis seeds, such as shampoos, soaps, and body





194 lotions (if the products do not cause THC to enter the human  
195 body); and

196 (v) Processed cannabis plant extract, oil or  
197 resin with a minimum ratio of twenty-to-one cannabidiol to  
198 tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and  
199 diluted so as to contain at least fifty (50) milligrams of  
200 cannabidiol per milliliter, with not more than two and one-half  
201 (2.5) milligrams of tetrahydrocannabinol per milliliter;

202 (32) Phencyclidine;

203 (33) Ethylamine analog of phencyclidine (PCE);

204 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);

205 (35) Thiophene analog of phencyclidine;

206 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);

207 (37) 4-methylmethcathinone (mephedrone);

208 (38) 3,4-methylenedioxypropylvalerone (MDPV);

209 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);

210 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);

211 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

212 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

213 or 2,5-dimethoxy-4-iodophenethylamine;

214 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine

215 (2C-T-2);

216 (44)

217 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

218 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);



219 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);  
220 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine  
221 (2C-P);  
222 (48) 3,4-methylenedioxy-N-methylcathinone (methydone);  
223 (49)  
224 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
225 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);  
226 (50)  
227 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
228 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);  
229 (51)  
230 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or  
231 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;  
232 Cimbi-5);  
233 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,  
234 4-benzodiazepin-2-one (also known as Phenazepam);  
235 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,  
236 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene  
237 (also known as Etizolam);  
238 (54) Salvia divinorum;  
239 (55) Synthetic cannabinoids. Unless specifically  
240 excepted or unless listed in another schedule, any material,  
241 compound, mixture, or preparation which contains any quantity of a  
242 synthetic cannabinoid found in any of the following chemical  
243 groups, whether or not substituted to any extent, or any of those



244 groups which contain any synthetic cannabinoid salts, isomers, or  
245 salts of isomers, whenever the existence of such salts, isomers,  
246 or salts of isomers is possible within the specific chemical  
247 designation, including all synthetic cannabinoid chemical  
248 analogues in such groups:

249 (A) (6aR,10aR)-9-(hydroxymethyl)-6,  
250 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]  
251 chromen-1-ol (also known as HU-210 or  
252 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

253 (B) Naphthoylindoles and naphthylmethylindoles,  
254 being any compound structurally derived from 3-(1-naphthoyl)indole  
255 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted  
256 in the indole ring to any extent, or in the naphthyl ring to any  
257 extent;

258 (C) Naphthoylpyrroles, being any compound  
259 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not  
260 substituted in the pyrrole ring to any extent, or in the naphthyl  
261 ring to any extent;

262 (D) Naphthylmethylindenes, being any compound  
263 structurally derived from 1-(1-naphthylmethyl)indene, whether or  
264 not substituted in the indene ring to any extent or in the  
265 naphthyl ring to any extent;

266 (E) Phenylacetylindoles, being any compound  
267 structurally derived from 3-phenylacetylindole, whether or not



268 substituted in the indole ring to any extent or in the phenyl ring  
269 to any extent;

270 (F) Cyclohexylphenols, being any compound  
271 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether  
272 or not substituted in the cyclohexyl ring to any extent or in the  
273 phenolic ring to any extent;

274 (G) Benzoylindoles, whether or not substituted in  
275 the indole ring to any extent or in the phenyl ring to any extent;

276 (H) Adamantoylindoles, whether or not substituted  
277 in the indole ring to any extent or in the adamantoyl ring system  
278 to any extent;

279 (I) Tetrahydro derivatives of cannabinal and  
280 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,  
281 except where contained in cannabis or cannabis resin;

282 (J) 3-Cyclopropylmethanone indole or  
283 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by  
284 substitution at the nitrogen atom of the indole ring, whether or  
285 not further substituted in the indole ring to any extent, whether  
286 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl  
287 rings to any extent;

288 (K) Quinoliny ester indoles, being any compound  
289 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny  
290 ester, whether or not substituted in the indole ring to any extent  
291 or the quinolone ring to any extent;



292 (L) 3-carboxamide-1H-indazoles, whether or not  
293 substituted in the indazole ring to any extent and substituted to  
294 any degree on the carboxamide nitrogen and  
295 3-carboxamide-1H-indoles, whether or not substituted in the indole  
296 ring to any extent and substituted to any degree on the  
297 carboxamide nitrogen;

298 (M) Cycloalkanemethanone Indoles, whether or not  
299 substituted at the nitrogen atom on the indole ring, whether or  
300 not further substituted in the indole ring to any extent, whether  
301 or not substituted on the cycloalkane ring to any extent.

302 (d) **Depressants.** Unless specifically excepted or unless  
303 listed in another schedule, any material, compound, mixture, or  
304 preparation which contains any quantity of the following  
305 substances having a depressant effect on the central nervous  
306 system, including their salts, isomers, and salts of isomers,  
307 whenever the existence of such salts, isomers, and salts of  
308 isomers is possible within the specific chemical designation:

309 (1) Gamma-hydroxybutyric acid (other names include:  
310 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic  
311 acid; sodium oxybate; sodium oxybutyrate);

312 (2) Mecloqualone;

313 (3) Methaqualone.

314 (e) **Stimulants.** Any material, compound, mixture or  
315 preparation which contains any quantity of the following central  
316 nervous system stimulants including optical salts, isomers and



317 salts of isomers unless specifically excepted or unless listed in  
318 another schedule:

319 (1) Aminorex;

320 (2) N-benzylpiperazine (also known as BZP;  
321 1-benzylpiperazine);

322 (3) Cathinone;

323 (4) Fenethylamine;

324 (5) Methcathinone;

325 (6) 4-methylaminorex (also known as  
326 2-amino-4-methyl-5-phenyl-2-oxazoline);

327 (7) N-ethylamphetamine;

328 (8) Any material, compound, mixture or preparation  
329 which contains any quantity of N,N-dimethylamphetamine. (Other  
330 names include: N,N,-alpha-trimethyl-benzeneethanamine, and  
331 N,N-alpha-trimethylphenethylamine);

332 (9) **Synthetic cathinones.** (A) Unless listed in  
333 another schedule, any compound other than bupropion that is  
334 structurally derived from 2-Amino-1-phenyl-1-propanone by  
335 modification in any of the following ways:

336 (i) By substitution in the phenyl ring to any  
337 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide  
338 substituents, whether or not further substituted in the phenyl  
339 ring by one or more other univalent substituents;

340 (ii) By substitution at the 3-position with  
341 an alkyl substituent;



342 (iii) By substitution at the nitrogen atom  
343 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom  
344 in a cyclic structure.

345 (B) The compounds covered in this paragraph (9)  
346 include, but are not limited to, any material compound, mixture or  
347 preparation which contains any quantity of a synthetic cathinone  
348 found in any of the following compounds, whether or not  
349 substituted to any extent, or any of these compounds which contain  
350 any synthetic cathinone, or salts, isomers, or salts of isomers,  
351 whenever the existence of such salts, isomers or salts of isomers  
352 is possible, unless specifically excepted or listed in another  
353 schedule:

354 (i) 4-methyl-N-ethylcathinone ("4-MEC");

355 (ii) 4-methyl-alpha-pyrrolidinopropiophenone  
356 ("4-MePPP");

357 (iii) Alpha-pyrrolidinopentiophenone  
358 (" $\alpha$ -PVP");

359 (iv)  
360 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone");

361 (v) 2-(methylamino)-1-phenylpentan-1-one  
362 ("pentedrone");

363 (vi)  
364 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one

365 ("pentylone");

366 (vii) 4-fluoro-N-methylcathinone ("4-FMC");



367 (viii) 3-fluoro-N-methylcathinone ("3-FMC");  
368 (ix)  
369 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one ("naphyrone");  
370 and  
371 (x) Alpha-pyrrolidinobutiophenone ("α-PBP").

372 **SECTION 2.** Section 41-29-115, Mississippi Code of 1972, is  
373 amended as follows:

374 41-29-115. (A) The controlled substances listed in this  
375 section are included in Schedule II.

376 **SCHEDULE II**

377 (a) **Substances, vegetable origin or chemical synthesis.**

378 Any of the following substances, except those narcotic drugs  
379 listed in other schedules, whether produced directly or indirectly  
380 by extraction from substances of vegetable origin, or  
381 independently by means of chemical synthesis, or by combination of  
382 extraction and chemical synthesis:

383 (1) Opium and opiate, and any salt, compound,  
384 derivative, or preparation of opium or opiate, excluding  
385 apomorphine, thebaine-derived butorphanol, dextrorphan,  
386 nalbuphine, nalmefene, naloxegol, naloxone and naltrexone, but  
387 including the following:

- 388 (i) Codeine;  
389 (ii) Dihydroetorphine;  
390 (iii) Ethylmorphine;  
391 (iv) Etorphine hydrochloride;





- 392 (v) Granulated opium;
- 393 (vi) Hydrocodone, whether alone or in  
394 combination with any material, compound, mixture or preparation;
- 395 (vii) Hydromorphone;
- 396 (viii) Metopon;
- 397 (ix) Morphine;
- 398 (x) Opium extracts;
- 399 (xi) Opium fluid extracts;
- 400 (xii) Oripavine;
- 401 (xiii) Oxycodone;
- 402 (xiv) Oxymorphone;
- 403 (xv) Powdered opium;
- 404 (xvi) Raw opium;
- 405 (xvii) Thebaine;
- 406 (xviii) Tincture of opium.
- 407 (2) Any salt, compound, isomer, derivative, or  
408 preparation thereof which is chemically equivalent or identical  
409 with any of the substances referred to in paragraph (1), but not  
410 including the isoquinoline alkaloids of opium;
- 411 (3) Opium poppy and poppy straw;
- 412 (4) Coca leaves and any salt, compound,  
413 derivative, or preparation of cocaine or coca leaves, including  
414 cocaine and ecgonine and any salt, compound, derivative, isomer,  
415 or preparation thereof which is chemically equivalent or identical  
416 with any of these substances, but not including:



417 (i) Decocainized coca leaves or extraction of  
418 coca leaves, which extractions do not contain cocaine or ecgonine;  
419 or

420 (ii) Ioflupane;

421 (5) Concentrate of poppy straw (the crude extract  
422 of poppy straw in either liquid, solid or powder form which  
423 contains the phenanthrene alkaloids of the opium poppy).

424 (b) **Opiates.** Any of the following opiates, including  
425 their isomers, esters, ethers, salts, and salts of isomers,  
426 whenever the existence of these isomers, esters, ethers and salts  
427 is possible within the specified chemical designation, dextrorphan  
428 and levopropoxyphene excepted:

429 (1) Alfentanil;

430 (2) Alphaprodine;

431 (3) Anileridine;

432 (4) Bezitramide;

433 (5) Bulk dextropropoxyphene (nondosage forms);

434 (6) Carfentanil;

435 (7) Dihydrocodeine;

436 (8) Diphenoxylate;

437 (9) Fentanyl;

438 (10) Isomethadone;

439 (11) Levo-alpha-acetylmethadol

440 (levo-alpha-acetylmethadol, levomethadyl acetate, LAAM);

441 (12) Levomethorphan;



442 (13) Levorphanol;  
443 (14) Metazocine;  
444 (15) Methadone;  
445 (16) Methadone-intermediate,  
446 4-cyano-2-dimethylamino-4,4-diphenyl butane;  
447 (17) Moramide-intermediate,  
448 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;  
449 (18) Pethidine (meperidine);  
450 (19) Pethidine-Intermediate-A,  
451 4-cyano-1-methyl-4-phenylpiperidine;  
452 (20) Pethidine-Intermediate-B,  
453 ethyl-4-phenylpiperidine-4-carboxylate;  
454 (21) Pethidine-Intermediate-C,  
455 1-methyl-4-phenylpiperidine-4-carboxylic acid;  
456 (22) Phenazocine;  
457 (23) Piminodine;  
458 (24) Racemethorphan;  
459 (25) Racemorphan;  
460 (26) Remifentanil;  
461 (27) Sufentanil;  
462 (28) Tapentadol \* \* \*;  
463 (29) Thiafentanil,  
464 4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-[2-(thienyl)ethyl  
465 ]piperidine.



466 (c) **Stimulants.** Any material, compound, mixture, or  
467 preparation which contains any quantity of the following  
468 substances:

469 (1) Amphetamine, its salts, optical isomers, and  
470 salts of its optical isomers;

471 (2) Phenmetrazine and its salts;

472 (3) Any substance which contains any quantity of  
473 methamphetamine, including its salts, isomers, and salts of  
474 isomers;

475 (4) Methylphenidate and its salts;

476 (5) Lisdexamfetamine, its salts, isomers and salts  
477 of isomers.

478 (d) **Depressants.** Unless listed in another schedule,  
479 any material, compound, mixture, or preparation which contains any  
480 quantity of the following substances:

481 (1) Amobarbital;

482 (2) Secobarbital;

483 (3) Pentobarbital;

484 (4) Glutethimide.

485 (e) **Hallucinogenic substances.**

486 (1) Dronabinol oral solution

487 [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)];

488 (2) Nabilone [other names include:

489 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-

490 hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].



491 (f) **Immediate precursors.** Unless specifically excepted  
492 or unless listed in another schedule, any material, compound,  
493 mixture, or preparation which contains any quantity of the  
494 following substances:

495 (1) Amphetamine and methamphetamine immediate  
496 precursor: Phenylacetone (other names include:  
497 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl  
498 ketone);

499 (2) Phencyclidine immediate precursors:  
500 (i) 1-phenylcyclohexylamine;  
501 (ii) 1-piperidinocyclohexanecarbonitrile  
502 (PCC);

503 (3) Fentanyl immediate precursor:  
504 4-anilino-N-phenethyl-4-piperidine (ANPP).

505 (B) Any material, compound, mixture or preparation which  
506 contains any quantity of a Schedule II controlled substance and is  
507 listed as an exempt substance in 21 CFR, Section 1308.24 or  
508 1308.32, shall be exempted from the provisions of the Uniform  
509 Controlled Substances Law.

510 **SECTION 3.** This act shall take effect and be in force from  
511 and after its passage.

